 13 PM / in 11 minutes BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007 Reuters Staff 1 Min Read 
Jan 30 (Reuters) - Fibrocell Science Inc: 
* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) 
* FIBROCELL SCIENCE INC - FCX-007, COâ€˜S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION  